Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 439 000 KRW 4.15% Market Closed
Market Cap: 23.4T KRW
Have any thoughts about
Alteogen Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-4 566.8
Current
-158
Median
4.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-4 566.8
=
Enterprise Value
23.2T KRW
/
EBITDA
-5.1B KRW
All Countries
Close
Market Cap EV/EBITDA
KR
Alteogen Inc
KOSDAQ:196170
23.3T KRW -4 566.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 796.7
US
Abbvie Inc
NYSE:ABBV
300.2B USD 14.8
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 17.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD 26.7
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 10.1
US
Epizyme Inc
F:EPE
94.1B EUR -521.2
AU
CSL Ltd
ASX:CSL
137.3B AUD 20.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 17.3
US
Seagen Inc
F:SGT
39.3B EUR -59.5
NL
argenx SE
XBRU:ARGX
34.1B EUR -104.5
EBITDA Growth
KR
Alteogen Inc
KOSDAQ:196170
Average EV/EBITDA: 17.9
Negative Multiple: -4 566.8
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.8
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-4 986.9
2-Years Forward
EV/EBITDA
661.1
3-Years Forward
EV/EBITDA
54.8

See Also

Discover More